Clinical trials: Ovary Cancer
Solid Tumor
Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of RMC-4630 and cobimetinib in adult participants with relapsed/refractory solid tumors with specific…
- Trial name
- NCT03989115
- Testing
- RMC-4630, Cobimetinib, Drug: Osimertinib
- Where
- 24 sites in United States, South Korea
- Volunteers
- 113 people
- Sponsor
- Revolution Medicines, Inc.
Cervical Cancer, Endometrial Cancer
CerviPrep for Applying Topical Gemcitabine to the Cervix in Treating Patients With Primary Endometrial, Cervical, or Ovarian Epithelial Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Cervical Cancer, Endometrial Cancer, Ovarian Cancer
- Trial name
- NCT00610740
- Testing
- topical gemcitabine hydrochloride, therapeutic conventional surgery
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer
Hyperthermic Intraperitoneal Chemotherapy Trial Comparing Quality of Life in Patients With Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This phase II trial studies how well hyperthermic intraperitoneal chemotherapy works in improving quality of life in patients with stage IIIC-IV ovarian, fallopian tube, or primary peritoneal cancer.
- Conditions
- Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer
- Trial name
- NCT03188432
- Testing
- Carboplatin, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Wake Forest University Health Sciences
Metastatic High Grade Fallopian Tube Serous Adenocarcinoma, Metastatic Malignant Solid Neoplasm
Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer
This phase I trial studies the side effects and best dose of olaparib and onalespib when given together in treating patients with solid tumors that have spread to other places in the body (metastatic) or cannot be removed by…
- Conditions
- Metastatic High Grade Fallopian Tube Serous Adenocarcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Primary Peritoneal Serous Adenocarcinoma, Metastatic Triple-Negative Breast Carcinoma
- Trial name
- NCT02898207
- Testing
- Olaparib, Onalespib
- Where
- 8 sites in United States
- Volunteers
- 28 people
- Sponsor
- National Cancer Institute (NCI)
Fallopian Tube Cancer, Female Reproductive Cancer
Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer
This trial is studying the side effects and best dose of ixabepilone when given together with pegylated liposomal doxorubicin hydrochloride and to see how well they work in treating women with advanced ovarian epithelial, primary…
- Conditions
- Fallopian Tube Cancer, Female Reproductive Cancer, Recurrent Breast Cancer, Recurrent Ovarian Epithelial Cancer
- Trial name
- NCT00182767
- Testing
- ixabepilone, pegylated liposomal doxorubicin hydrochloride
- Where
- 5 sites in United States
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Carcinoma, Primary Peritoneal Carcinoma
Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian Primary Peritoneal Carcinoma
The purpose of this study is to determine if the combination of bevacizumab and pemetrexed have an effect on recurrent ovarian and primary peritoneal carcinoma by looking at progression and survival at 6 months.
- Trial name
- NCT00868192
- Testing
- Pemetrexed, Bevacizumab
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Washington University School of Medicine
Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor
Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors
RATIONALE: Drugs used in chemotherapy, such as cisplatin, ifosfamide, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Ovarian Cancer, Teratoma
- Trial name
- NCT00470366
- Testing
- pegfilgrastim, cisplatin, ifosfamide
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Epithelial Ovarian Cancer
Safety and Efficacy Clinical Study of SNS-595 in Patients With Platinum-Resistant Ovarian Cancer
The purpose of this study is to evaluate the objective response rate, safety and identify potential biomarkers in platinum-resistant ovarian cancer patients treated with voreloxin injection given on a 28-day cycle.
- Trial name
- NCT00408603
- Testing
- Voreloxin Injection
- Where
- 20 sites in United States, Canada
- Volunteers
- 183 people
- Sponsor
- Sunesis Pharmaceuticals
Ovarian Neoplasms, Non-Small-Cell Lung Carcinoma
A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers.
A phase I study of LTT462 in patients with advanced solid tumors that harbor MAPK pathway alterations.
- Conditions
- Ovarian Neoplasms, Non-Small-Cell Lung Carcinoma, Melanoma, Other Solid Tumors
- Trial name
- NCT02711345
- Testing
- LTT462
- Where
- 7 sites in United States, Germany and 4 more
- Volunteers
- 65 people
- Sponsor
- Novartis Pharmaceuticals
Ovarian Cancer, Fallopian Tubes Cancer
Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
The purpose of this study is to see if the investigators can improve the treatment of this type of cancer. They want to find out what effects, good and/or bad, giving heated chemotherapy into the belly, known as hyperthermic…
- Conditions
- Ovarian Cancer, Fallopian Tubes Cancer, Peritoneal Cancer
- Trial name
- NCT01767675
- Testing
- Secondary Cytoreductive Surgery, Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC), platinum-based systemic chemotherapy postoperatively
- Where
- 11 sites in United States
- Volunteers
- 99 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-small Cell Lung Cancer, Pancreatic Cancer
Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia
Study to compare the effects of the investigational new drug (PF-06946860) and a placebo on appetite and to find out how participants with advanced cancer and anorexia feel after receiving repeated subcutaneous (SC-injected under…
- Conditions
- Non-small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, Prostate Cancer
- Trial name
- NCT04803305
- Testing
- PF-06946860
- Where
- 33 sites in United States, Canada
- Volunteers
- 18 people
- Sponsor
- Pfizer
Platinum Sensitive, BRCA Mutated
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
A Phase III, randomised, double-blind, placebo-controlled, multi-centre study to assess the efficacy of olaparib maintenance monotherapy in relapsed high grade serous ovarian cancer (HGSOC) patients (including patients with…
- Conditions
- Platinum Sensitive, BRCA Mutated, Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy
- Trial name
- NCT01874353
- Testing
- Olaparib 300mg tablets
- Where
- 126 sites in United States, Australia and 15 more
- Volunteers
- 327 people
- Sponsor
- AstraZeneca
Ovarian Carcinoma, Breast Cancer
Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast Cancer
This is a Phase II, open label, non randomized correlative study of AZD2281 in patients with recurrent breast and ovarian cancer in both BRCA inherited mutation carriers and non-carriers to identify objective response rate and to…
- Trial name
- NCT00679783
- Testing
- AZD2281
- Where
- 6 sites in Canada
- Volunteers
- 99 people
- Sponsor
- AstraZeneca
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
The purpose of this study is to look at how patients respond to treatment with guadecitabine and pembrolizumab. The researchers will also be looking at the amount of time it takes for cancer to get worse when participants take…
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT02901899
- Testing
- Guadecitabine, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- 3 sites in United States
- Volunteers
- 45 people
- Sponsor
- Northwestern University
Ovarian Cancer, Peritoneal Cancer
A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
This is a Phase II, randomized, placebo-controlled, double-blind, multicenter clinical trial of pertuzumab in combination with gemcitabine relative to placebo in combination with gemcitabine in subjects with advanced ovarian…
- Conditions
- Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- NCT00096993
- Testing
- Gemcitabine, Pertuzumab
- Where
- 41 sites in United States
- Volunteers
- 131 people
- Sponsor
- Genentech, Inc.
Ovarian Cancer, Primary PERITONEUM
Intravenous and Intraperitoneal Paclitaxel, Intraperitoneal Cisplatin, and Intravenous Bevacizumab for the Initial Treatment of Optimal Stage II or III Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
The purpose of this study is to test whether it is safe to treat your cancer with 3 drugs instead of 2 drugs. After surgery, your cancer is typically treated with 2 drugs called cisplatin and paclitaxel (also known as Taxol).
- Conditions
- Ovarian Cancer, Primary PERITONEUM, Fallopian Tube Cancer
- Trial name
- NCT00588237
- Testing
- Paclitaxel,Cisplatin, Bevacizumab
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Polycystic Ovary Syndrome, Hyperandrogenism
Effect of Metformin on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone
Many, but not all, girls with high levels of the male hormone testosterone go on to develop polycystic ovary syndrome (PCOS) as adults.
- Trial name
- NCT01427595
- Testing
- Metformin, Progesterone, estrace
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Virginia
Epithelial Ovarian Cancer
Ovarian Cancer Vaccine for Patients in Remission
The purpose of this study is to determine the safety and efficacy of an investigational therapeutic agent (Cvac) in ovarian cancer patients in first or second remission and to determine its ability to prevent cancer from…
- Trial name
- NCT01068509
- Testing
- Cvac
- Where
- 18 sites in United States, Australia
- Volunteers
- 63 people
- Sponsor
- Prima BioMed Ltd
Fallopian Tube Carcinoma, Ovarian Carcinoma
DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission
This partially randomized phase I/IIb trial studies the side effects and best dose of IDO1 inhibitor INCB024360 in combination with DEC-205/NY-ESO-1 fusion protein CDX-1401 and poly ICLC and to see how well they work in treating…
- Conditions
- Fallopian Tube Carcinoma, Ovarian Carcinoma, Primary Peritoneal Carcinoma
- Trial name
- NCT02166905
- Testing
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Epacadostat, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Roswell Park Cancer Institute
Platinum Resistant Ovarian Cancer
FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer
This is a multicenter, multinational, randomized, double-blind, 2-arm, parallel-group, Phase 2/3 study to evaluate the efficacy and safety of PCC plus bevacizumab and CA4P versus PCC plus bevacizumab and placebo in subjects with…
- Trial name
- NCT02641639
- Testing
- Fosbretabulin tromethamine
- Where
- 40 sites in United States, Belgium and 1 more
- Volunteers
- 70 people
- Sponsor
- Mateon Therapeutics